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Abstract: Economic analyses of patients’ costs are pertinent to improve effective healthcare services 
including the prevention of mother-to-child HIV/AIDS transmission (PMTCT). This study assessed the 
direct and non-direct medical costs borne by pregnant women attending PMTCT services in urban 
(high-HIV prevalence) and rural (low-HIV prevalence) settings, in Ethiopia. Patient-level direct 
medical costs and direct non-medical data were collected from HIV-positive pregnant women in six 
regions. The cost estimation was classified as direct medical (service fee, drugs and laboratory) and 
direct non-medical (food, transportation and accommodation). The mean direct medical expense per 
patient per year was Ethiopian birr (ETB) 746 (US$ 38) in the urban settings, as compared to ETB 368 
(US$ 19) in the rural settings. On average, a pregnant woman from urban and rural catchments incurred 
direct non-medical costs of ETB 6,435 (US$ 327) and ETB 2,154 (US$ 110) per year, respectively. On 
average, non-medical costs of friend/relative/guardian were ETB 2,595 (US$ 132) and ETB 2,919 (US$ 
148.39) in the urban and rural settings, respectively. Although the PMTCT service is provided free of 
charge, HIV-positive pregnant women and infant pairs still face a substantial amount of out-of-pocket 
spending due to direct medical and non-medical costs.  
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1. Introduction 
HIV/AIDS continues to challenge socio-economic progress across the globe. In 
particular, the disease has been affecting the socio-economic development of most 
sub-Saharan African (SSA) countries. In the region, the disease has caused a high 
number of new HIV infections posing serious threats to the lives of current and future 
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generations (UNAIDS, 2013). It also eroded the productive labor force in low-
income countries. Especially, the epidemic has impacted on the most vulnerable 
sections of society, such as children and women (Foster & Williamson, 2000). 
Globally, almost 90% of mother-to-child transmission of HIV/AIDS was reported in 
African countries (Vitoria et al., 2009). The vertical transmissions of HIV/AIDS 
from mother-to-infant accounts for a significant proportion of the total number of 
new HIV infection reported in SSA countries. It is documented that 15-30% of these 
vertical transmissions of HIV infections from mother-to-child occur during labor, 
delivery, pregnancy and breastfeeding (De Cock et al., 2000; World Health 
Organization [WHO], 2004, 2007b). Prevailing numbers of infant infections and low 
antiretroviral treatment coverage for pregnant women and infants, coupled with low 
domestic financial resources in these countries have made it difficult to achieve zero 
mother-to-child HIV infections by 2015 (Joint United Nations Programme on HIV 
and AIDS [UNAIDS], 2013). 
Part of this failure could be due to limited PMTCT services access and utilization, 
which in turn possibly arise from the economic out-of-pocket spending by patients 
while seeking PMTCT services. To date, most of the evidence on economic costs of 
HIV/AIDS and usage of HIV services in low-income countries has been produced at 
a macro level and studies have not focused on HIV-positive pregnant women. The 
most prominent of these macro-level analyses was conducted by the Institute of 
Health Metric Evaluation (IHME, 2013), which analyzed and reported on the 
regional and global burden of disease report, and included some disaggregated 
analysis for low-income countries. However, the report was not detailed enough to 
provide relevant evidence at the household economy level. A similar study consisted 
of a case study in Mozambique by Pessane and Soloman (2010), which reported on 
the impact of HIV/AIDS on economic growth through the erosion of human capital, 
an increase in absenteeism and a decline in workers’ productivity.The study further 
found that, beyond its short-term impact, HIV/AIDS was significantly hampering 
the country’s long-term economic growth, and led to a long-term threat to stability 
and development. In South Africa, a study reported on the overall impact of 
HIV/AIDS on the household economy, agriculture, other economic sectors and 
macro economy (Lori & Stover, 1999).  
At a micro-level, a study in Kenya compared the out-of-pocket payments among 
HIV-positive and HIV-negative patients in Kenyatta National Hospital (Guinness et 
al., 2002) and found that there was no cost variation irrespective of a patient’s HIV 
sero-status, suggesting that the cost factor was irrelevant to HIV status. In contrast, 
in the review of the literature on factors affecting HIV/AIDS service in low income 
countries, Souteyrand, Collard, Moatti, Grubb, and Guerma (2008) noted user fees 
as a critical barrier affecting antiretroviral treatment adherence. In Malawi, Pinto, 
van Lettow, Rachlis, Chan, and Sodhi (2013) compared patient costs differences 
among those who attended centralized and decentralized health facility settings. 
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According to Pinto et al. (2013), travel-related patients’ costs were significantly 
different across these two groups. In Ethiopia, related studies reported qualitative, 
descriptive and specific-context findings on the impact of out-of-pocket spending for 
effective HIV/AIDS prevention, care and treatment (Biadgilign, Deribew, Amberbir, 
& Deribe, 2009; Bollinger, Stover, & Seyoum, 1999; Federal Ministry [FMOH], 
2013; Tekola, Reniers, Haile Mariam, Araya, & Davey, 2008), but did not estimate 
the direct medical costs, direct non-medical costs and productivity loss of HIV-
positive pregnant women attending the PMTCT services.  
The economic cost of mother-to-child infection in sub-Saharan Africa can be best 
grasped through an understanding of the role played by women in the region. African 
women perform an active poverty reduction role in food crop processing, various 
levels of household chores, food storage and transportation, hoeing and weeding. 
Given women’s contribution to the economy of the households, the burden of 
HIV/AIDS on the HIV-positive pregnant women (attending their antiretroviral 
treatment) is likely to result in severe economic losses. However, little evidence 
exists from the perspective of HIV-positive pregnant women attending their lifelong 
antiretroviral treatment. In particular, this evidence is pertinent in light of the recent 
changing international PMTCT treatment protocol (WHO, 2007a, 2012). For 
instance, the recent PMTCT service protocol for the option B+ treatment regimen 
requires more frequent visits and consultations, and could probably cause excess out-
of-pocket spending for transportation, food and accommodation for HIV-positive 
pregnant women. In addition, these high medical expenses could in turn hamper 
effective utilization of PMTCT services, in particular for poor pregnant women from 
the rural country-side.  
The deficiency of evidence is particularly high in Ethiopia as no study has 
specifically analyzed the economic impact of HIV/AIDS at patient and household 
levels in the context of the PMTCT, as well as from heterogeneous HIV-prevalence 
and socio-economic (urban-rural) settings. Studies reporting the impact of 
HIV/AIDS in Ethiopia were conducted by Tekola et al. (2008) and Kloos and 
Mariam (2000), and reported the socio-economic burden of HIV/AIDS in specific 
parts of the country. Another study highlighted the broader economic impact of the 
disease on the households, agriculture, firms, other economic sectors and the macro 
economy (Bollinger et al., 1999). None of these studies analyzed the patient’s 
perspective on costing among HIV-positive pregnant women attending their lifelong 
antiretroviral treatment. To fill this gap, this study aimed to analyze the direct 
medical and direct non-medical costs among HIV-positive pregnant women 
attending health facilities in Ethiopia, and comparing the costs across urban-rural 
settings.  
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2. Methods 
2.1 Data collection 
Patient cost data were collected from 85 HIV-positive pregnant women attending 
their antiretroviral treatment, 17 Mother Support Groups (MSGs) and 12 healthcare 
professionals who were closely working with the patients. The patients attending 
their life-long antiretroviral treatment were recruited from the twelve health facilities 
(six urban high HIV-prevalence and six rural low HIV-prevalence facilities) across 
six regions in Ethiopia. Heterogeneity in HIV prevalence and urban-rural location 
were used as criteria to select twelve health facilities from the 2012 antenatal-based 
sentinel surveillance sites (Ethiopian Public Health Institute [EPHI], 2014). The 
survey was conducted from Aug 17 to Oct 2, 2015. The surveyed health facilitates 
are located in six regions of Ethiopia: Oromia, Amhara, South Nations and 
Nationality of People (SNNP), Harari, Addis Ababa and Dire Dawa. In accordance 
with the 2012 antenatal-based sentinel HIV surveillance data (EPHI, 2014), patients 
were recruited from six urban health facilities (Bahir Dar Hospital, Hiwot Fana 
Hospital, Dile Chora Hospital, Armed Forces Referral and Teaching Hospital 
(AFRTH), Soddo Health Center and Teklehaimanot Health Center), which had the 
highest HIV prevalence (8.8 to 17.3) across the country. Other groups of patients 
were interviewed from the rural and low-HIV prevalence health facilities (0.0 to 0.1), 
namely, Limuseka Health Center, Daddim Health Center, Toke Health Center, 
Chewaka Health Center, Kokosa Health Center and Hasange Health Center. 
As shown in Figure 1, patient perspective costing was analyzed and categorized into 
direct medical costs and direct non-medical costs. Direct medical costs included the 
direct expenses incurred by HIV-positive pregnant women while attending their 
antiretroviral treatment services such as: HIV counseling and testing, hospital 
admission, antiretroviral option B+ treatment follow-up and early infant diagnosis 
(EID) services. The analysis also considered the cost incurred by 
guardian/relatives/friends during the patient consultation visits. The second costing 
category was direct non-medical costs, which covered the cost of purchasing non-
medical supplies/equipment, which were not typically linked with the diagnosis or 
treatment. This comprised costing items such as: transportation, food and 
accommodation costs incurred by patients; and transportation, food and 
accommodation costs incurred by caregivers/friends/guardians.  
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Figure 1. Patient costing framework for direct medical costs and direct non-
medical costs 
The economic and financial costs attributed to HIV morbidity incurred by HIV-
infected mothers and their households were analyzed through a retrospective bottom-
up diagnostic-specific method (Akobundu, Ju, Blatt, & Mullins, 2006; Tarricone, 
2006). Patients attending the surveyed health facilities were requested to provide all 
the costing ingredients paid (during outpatient consultation and inpatient admission) 
retrospectively. Applying the bottom-up retrospective approach, the patient-level 
costing was conducted to estimate direct medical and direct non-medical costs paid 
by guardian/relatives/friends. The national-level patient perspective costs were 
estimated considering the final cost summary measure (per patient per year [PPY]) 
and country wide estimated number of HIV-positive pregnant women who were in 
need of treatment in urban and rural settings (Ethiopian Health and Nutrition 
Research Institute [EHNRI], 2012). A sensitivity analysis was conducted to estimate 
the national-patient cost using three scenarios: at the 57% current coverage level, at 
the 75% coverage level, and at 100% coverage level. The data were first entered 
using EpiData 3.1 software and transferred for analysis to the Statistical Package for 
the Social Sciences (SPSS) software version 22. Relevant statistical tests, t-tests 
(equal or non-equal variance assumptions) and Pearson chi-square tests were applied 
to compare results across urban-rural settings. 
Direct medical costs 
ingredients 
Direct non-medical 
costs ingredients 
Out of pocket expenses  
for card fees, laboratory 
tests, 
drug costs and 
inpatient hospital 
admission costs 
Transportation costs (by the 
patient and care giver/friend) 
Foods expenses (by the patient 
and care giver/friend) 
Accommodation expenses (by 
the patient and care 
giver/friend) 
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The patients’ costing tool was adopted from the KNCV tuberculosis foundation, 
WHO and Japan’s anti-tuberculosis association (Tuberclusosis Coalition for 
Techncial Assistance [TBCTA], 2007). It was piloted in two health facilities (Gandhi 
Memorial Hospital and Beletsheachew Health Center) in Addis Ababa. The tool 
comprised different sections: patient information, diagnostic costs, total time spent 
for HIV counseling and testing, treatment, care and support, costs related to the 
follow-up tests, guardian costs, hospitalization costs, food supplements, coping costs 
and productivity loss attributed to the HIV/AIDS illness. A supplementary interview 
guide was prepared to interview MSGs and health care professionals. National-level 
patient data were extracted from the Federal Ministry of Health (FMOH)/ Ethiopian 
Public Health Institute (EPHI) data base (EPHI, 2014), and further checked using 
the Health Management Information System (HMIS) database in six regional health 
bureaus (Oromia, Amhara, SNNP, Harari, Addis Ababa and Dire Dawa). 
 
2.2 Ethical Consideration 
The research project was approved by the University of KwaZulu-Natal (UKZN) 
Biomedical Research and Ethics Committee (BREC REF: BE385/14) and the 
Federal Ministry of Health/ Ethiopian Public Health Institute Scientific and Ethical 
Review Office (SERO REF: 6.13/80). An official letter of permission was obtained 
from the Federal Ministry of Health (FMOH) and Ethiopian Public Health Institute 
(EPHI) to the respective selected regional health bureaus and surveyed health 
facilities. An informed consent form was obtained from the HIV-positive pregnant 
women, Mother Support Groups and health professionals, before starting the data 
collection.  
 
3. Results and Discussion 
A total of 85 HIV-positive pregnant women were interviewed. As a way of 
exhausting all costs information (outpatient and inpatient) from women attending 
PMTCT services, additional costing inputs to be included in the costing sheets were 
solicited from 17 MSGs and 12 healthcare professionals who were closely working 
with the patients. Of all the HIV-positive pregnant women respondents interviewed 
in rural and urban facilities, the majority (66%) were from urban high-prevalence 
settings.  
3.1 Socio-demographic Characteristics 
Table 1 describes the socio-demographic characteristics of the respondents, notably 
age, educational status, occupation, marital status and household income earnings. 
The mean age of the respondents was 29 and 28, in urban and rural settings, 
respectively. Of the respondents from rural low-HIV settings, 62% were illiterate, 
while 43% had attained primary education in the urban high-HIV prevalence 
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settings. The data showed a statistical difference in the education status across urban-
rural settings (p < 0.001). In the urban settings, 68% of urban high-HIV prevalence 
respondents were permanently paid employees or had a trade/ business occupation, 
while 59% of the rural study participants were farmers, and engaged in various 
small-scale business activities (not shown in Table 1). A statistical difference was 
reported in the type of occupation among the urban-rural respondents (p < 0.001). 
Married patients comprised 66% in urban settings, and 34% in rural settings. Of all 
single participants, 100% were from urban settings against 0% in rural settings. The 
corresponding numbers of married and divorced people were 66% against 34%, 57% 
against 43%, respectively. 
A relatively higher proportion of the household income earners (across different 
categories), were reported in urban settings, as compared to the rural respondents. 
However, there was no statistical difference reported between the study participants 
across the urban and rural settings, respectively. Of the listed groups of the primary 
income earners, father/husband had a primary income role for 70% of respondents 
in urban settings and 30% in rural settings. The woman/wife was the primary income 
earner for 55% and 45% in urban and rural contexts, respectively. Most respondents 
had a monthly income of Ethiopian birr (ETB) 500 (United States dollar (USD) 
25.42) [1] and above in the urban settings, while the majority of rural respondents 
earned below ETB 500 (USD 25.42). Urban patients’ earned a relatively higher 
proportion of the household income as compared to those in the rural settings (Chi-
square, p < 0.001). This may be linked with the continuous low economic 
empowerment and primary income role played by women in rural settings, as 
compared to the educated, empowered women who are living in the commercial 
urban cities.  
Table 1. Socio-demographic characteristics of the respondents in urban and 
rural settings 
Socio-demographic 
variables 
Urban high-HIV 
prevalence settings  
Rural low-
HIV 
prevalence 
settings  
 
P-value 
N n= 56 n=29  
Age 29.39 (SD: 5.38) 
28.07 (SD: 
7.89) 0.085 
Educational status   0.000† 
Illiterate 5 (22%) 18 (78%)  
Basic Education 10 (83%)  2 (17%)  
Primary (grade 1-8) 24 (77%) 7 (23%)  
Secondary (grade 9-10) 9 (90%) 1 (10%)  
Preparatory (11-12) 3 (100%) 0 (0%)  
10+TVET 1 (100%) 0 (0%)  
College/university 4 (80%) 1(20%)  
                                                     
1 Prices are reported in 2014 Ethiopian birr (ETB) and converted to United States Dollar (USD) at the 
weighted exchange rate (1 US$ = 19.6705 ETB) from www.oanda.com, retrieved on 05 Nov 2015. 
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Occupation    
Farming 2 (15%) 11 (85%) 0.000† 
Wage labor 6 (60%) 4 (40%)  
Permanent paid employee 18 (100%) 0 (0%)  
Trade/business 20 (77%) 6 (23%)  
Student 2 (100%) 0 (0%)  
Housewife 1 (25%) 3 (75%)  
No occupation 7 (58%) 5 (42%)  
Marital status    
Single 4 (100%) 0 (0%) 0.346 
Married 47 (66%) 24 (34%)  
Divorced 4 (57%) 3 (43%)  
Widowed 1 (50%) 1 (50%)  
Live with partner 0 (0%) 1 (100%)  
Household income earner   0.634 
Patient 6 (55%) 5 (45 %)  
Wife/Mother 6 (55 %) 5 (45 %)  
Husband/ Father 42 (70 %) 18 (30 %)  
Extended family 2 (67 %) 1 (33 %)  
Household income (per 
month)   0.000† 
Under 500 ETB per month 6 (30 %) 14 (70 %)  
500 ETB to 750 ETB per 
month 10 (56 %) 8 (44 %)  
750 ETB to 1000 ETB per 
month 4 (57 %) 3 (43 %)  
More than 1000 ETB per 
month 23 (100 %) 0 (0 %)  
Don't earn 13 (76 %) 4 (24 %)  
NB. Because of the decimal rounding, the total does not sum up to 100%.  
† = Significant at p < 0.001  
 
A total of 131 respondents were recruited for the cost-of-illness questionnaires from 
three different groups: HIV-positive pregnant women attending the health facilities 
(n=85), MSG members (n=34) and health care workers (n=12). This was due to low 
PMTCT attendance by HIV-positive pregnant women in surveyed health facilities. 
According to the previously conducted surveys by the FMOH and UNAIDS (FMOH, 
2012, 2014, 2015; UNAIDS, 2013), a low service uptake exists among the expected 
HIV-positive pregnant women across the country. For instance, in 2011/12, of the 
targeted HIV-positive pregnant women only 25.5% accessed and accepted the 
service (FMOH, 2012). In particular, two interview sessions (with MSGs and health 
care workers) were considered to substantiate whether or not any patients’ cost data 
were missed or ignored during interview sessions with HIV-positive pregnant 
women (option B+ regimen) respondents. In addition, the interview sessions with 
MSGs and health workers were used to gain more insight into the relevant patient 
costing ingredients to include in the questionnaire to be given to the pregnant women 
and to use in the datasheet.  
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3.2 Direct Medical Costs 
An HIV-positive pregnant woman-infant attending lifelong antiretroviral treatment 
(ART) incurred direct medical costs of ETB 746.00 (US$ 37.92) per year in urban 
high HIV-prevalence settings and ETB 368.40 (US$ 18.73) per year in rural low 
HIV-prevalence areas. The urban direct medical spending per pregnant women cost 
twice the amount spent in the rural settings. Of the listed direct medical cost 
categories, antibiotic drug costs, health facility sheets (patient admission), drugs 
costs during inpatient admission and laboratory test costs (during patient admission) 
were significantly higher in urban settings, relative to the rural settings (p < 0.05). 
However, there was no statistical significance between urban-rural respondents for 
the direct medical costing ingredients notably: HIV counseling and testing fees (card 
fee/consultative), health facility administration fees (for the admitted patients), other 
co-infections tests (including TB) costs and other co-infections drugs.  
The detailed list of direct medical cost findings is described in Table 2. Similarly, a 
study by Pearson, Gandhi, Admasu, and Keyes (2011) indicated that, although 
service utilization was at a low level in Ethiopia, pregnant women still incurred costs 
for drugs and supplies. The study further finds that 65% of the surveyed health 
facilities in Ethiopia still charge user fees for maternity services. In South Africa, 
similar findings were reported on the additional cost of purchasing non-prescriptive 
drugs and food for 60% of patients on ART (Rosen, Ketlhapile, Sanne, and DeSilva 
(2007), while high costs of medical HIV/AIDS services affecting the household 
economy were reported in Kenya (Guinness. et al., 2002). 
Table 2. Direct medical costs per patient per year in urban-rural settings 
Direct 
Medical Cost 
Variables 
Settings 
Mean 
(ETB) 
Std. 
Deviation 
Std. 
Error 
Mean 
F Sig. t df 
HIV 
counseling & 
testing fees 
(card fee, 
consultative)  
Urban 
settings 
1.18 6.74 0.90 
0.07 0.79 
-
0.02 83.00 
Rural 
settings 
1.21 2.18 0.40 
    
-
0.03 73.54 
Antibiotic 
drug costs 
(relevant for 
ART 
treatment and 
to treat other-
co-infections) 
Urban 
settings 
29.11 73.05 9.76 
21.92 0.00† 2.14 83.00 
Rural 
settings 
0.00 0.00 0.00 
    2.98 55.00 
Health facility 
administration 
fees (for the 
admitted 
patients) 
Urban 
settings 
48.97 134.39 23.05 
0.35 0.56 -
1.21 
49.00 
Rural 
settings 
92.06 84.00 20.37 
    -
1.40 
46.35 
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Health facility 
Sheets/Linnen 
fees (for the 
admitted 
patients) 
Urban 
settings 
132.06 116.80 20.03 
13.54 0.00† 3.75 50.00 
Rural 
settings 
22.78 54.64 12.88 
    4.59 49.50 
Drugs cost  
(during the 
inpatient 
admission) 
Urban 
settings 
249.45 252.59 45.37 
10.09 0.00† 2.24 45.00 
Rural 
settings 
104.00 77.33 19.33 
    2.95 39.29 
Tests cost 
(during the 
inpatient 
admission) 
Urban 
settings 
67.03 87.99 15.80 
4.40 0.04†† 0.70 44.00 
Rural 
settings 
50.07 47.91 12.37 
    0.85 43.24 
Other co-
infections 
tests costs 
Urban 
settings 
74.25 213.73 47.79 
2.53 0.12 0.70 30.00 
Rural 
settings 
30.42 45.10 13.02 
    0.88 21.72 
Other co-
infection 
drugs costs 
Urban 
settings 
53.25 199.96 44.71 
1.80 0.19 0.75 30.00 
Rural 
settings 
9.58 19.36 5.59 
    0.97 19.59 
Fees (related 
with the 
follow up 
tests) 
Urban 
settings 
13.80 33.39 6.68 
2.17 0.15 0.06 41.00 
Rural 
settings 
13.33 14.75 3.48 
    0.06 35.13 
Total direct 
medical costs 
per pregnant 
women-infant 
pair 
Urban 
settings 
746.00 749.68 207.92 
1.77 0.20 1.10 16.00 
Rural 
settings 
368.40 161.91 72.41 
    1.72 14.45 
† Statistical significance at P < 0.001 
††Statistical significance at P < 0.05 
 
3.3 Direct Non-medical Costs 
The mean transportation cost per pregnant women per year was ETB 1,276.07 (US$ 
64.87) and ETB 636.67 (US$ 32.37) in urban and rural settings, respectively. The 
transportation cost by patient in the urban settings was double compared to the one 
in the rural settings. This may be related to the fact that urban HIV-positive pregnant 
women pay more for available transportation to the health facilities than do rural 
respondents who are more likely to have to walk to reach the facilities. Of the 
different transportation-linked activities, travel costs due to other co-infectious 
diseases and ART treatment follow-up activities contributed the lion’s share in both 
the urban and rural settings. These findings line up with the evidence in Malawi 
where travel expense was the major contributor to patient costs to access HIV/AIDS 
care services (Pinto et al., 2013). 
ŒCONOMICA 
 201 
As for the transportation cost paid by patients, the travel expenses paid by the 
friends/guardians/partners were high. Friends/guardians/partners spent the means 
cost of ETB 1,783.73 (US$ 90.68) and ETB 2,066.44 (US$ 105.05) in urban and 
rural settings, respectively. A relatively higher travel cost was incurred in rural as 
compared to the urban settings. This may be related to more solidarity and 
companionship in the rural countryside, as compared to in the urban settings. Of the 
listed transportation cost breakdown, friends/guardians/partners spent more than 
85% of the cost proportion, in both the urban and rural settings, during the inpatient 
health facility admission. This was due to a significantly higher frequency of visits 
in rural settings (Mean = 20), as compared to the rural settings (Mean=14) (p < 0.05). 
Moreover, there was also a significant cost variation estimated on the transportation 
costs paid by relatives in urban-rural settings, during the inpatient admission.  
With respect to food expenditure, an average pregnant women per year (attending 
option B+ treatment regimen) from the urban settings spent ETB 4,700.50 (US$ 
238.96) for food items in the urban settings, while it was ETB 1,510.83 (US$ 76.81) 
in the rural settings. Food cost (per PPY) in a household (attributed to HIV illness) 
in the urban settings was more than twice the expense estimated in the rural settings 
(p < 0.05). This may be explained by the increased awareness of the HIV-positive 
population of the need for a nutritionally balanced diet in the urban settings, and 
relatively higher household income. Moreover, there was also a statistical variation 
reported on food expenses (during ART initiation and counseling), food costs 
(during the CD4 blood sample testing service), food costs (during the monthly ART 
drug refilling and counseling) and food costs (during linking the patient to care and 
support services).  
Friends/relatives/guardians spent non-medical costs on food items for accompanying 
the HIV-positive pregnant women, starting from HIV/AIDS counseling and testing 
to the antiretroviral treatment follow-up. These costs included food expenses during 
the HIV/AIDS counseling and testing, during the CD4 count blood sample service, 
during the early infant diagnosis/ dry blood testing, during ART initiation and 
follow-up, and during the inpatient admission. The mean cost of food by 
friends/relatives/guardians was ETB 811.29 (US$ 41.24) (SD = 403.72) and ETB 
832.78 (US$ 42.34) (SD = 783.64) in urban and rural settings, respectively. The 
mean food expense of ETB 253.36 (US$ 12.88) was estimated per patient per year 
(during ART initiation, drug refilling and follow-up) in the urban settings as 
compared to ETB 140.74 (US$ 7.15) expenses in the rural settings (p < 0.001). 
During the inpatient hospital admission, the mean food cost by relatives was ETB 
670.88 (US$ 34.11) in the rural areas, as compared to ETB 482.06 (US$ 24.51) in 
the urban areas.  
The mean accommodation expense per patient per year was ETB 458.54 (US$ 23.31) 
in urban settings, as compared to ETB 6.90 (US$ 0.35) in rural settings (p < 0.001). 
Of all the accommodation costing categories in the urban settings, the 
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accommodation expense by patients (during the monthly ART drug refilling and 
counseling) accounts for the highest proportion of costs. This was due to the frequent 
monthly visit (including hospital admissions) by the patients for drug refilling, 
treatment and counseling services. As compared to the urban settings, patients from 
the rural areas did not incur any accommodation expense during ART initiation and 
counseling, during the Early Infant Diagnosis (EID) testing, during the monthly ART 
drug refilling and counseling and while linking care and support services. The cost 
variation reported in the urban and rural settings was possibly related to the relatively 
higher hospital admission fees, as compared to the insignificant (or almost free of 
charge) costs in the remote rural health facilities.  
Unlike the expense for food and transportation, friends/relatives/guardians incurred 
a significantly lower proportion of the cost for accommodation expenses, both in the 
urban and rural settings. The mean accommodation cost (by 
friends/guardians/partners) per PPY was ETB 19.67 (US$ 1.01) in rural settings, as 
compared to ETB 0.00 (US$ 0.0) in the urban settings (p < 0.001). None of the 
respondents indicated the accommodation-related expense during the patient’s 
outpatient consultation for HIV/AIDS counseling and testing, the CD4 count service, 
EID service, and ART initiation, drug refilling and follow-up. Most of these 
activities were conducted during the daily consultation visits, without incurring 
additional accommodation-related expenses by the third parties. Notably, a higher 
accommodation cost was estimated in the rural settings, as compared to the urban 
settings. This was probably due to higher solidarity from friends/guardians/partners 
and closer companionship during the inpatient admission in the rural settings, as 
compared to the urban.  
3.4 Summary Cost Estimate 
Table 3 indicates the direct medical and direct non-medical cost estimate per HIV-
positive pregnant women per year. Analyzed from within each setting, food cost was 
the cost driver in the urban settings, while transportation cost (by 
friends/relatives/guardians) was the main contributor in rural settings. Of the listed 
non-medical cost items, food costs and transport costs were the main cost contributor 
in both the urban and rural settings. As compared to patients, 
friends/relatives/guardians spent the highest proportion of expenses for 
transportation in both settings. This was probably due to the higher frequency of 
friends/relatives/guardians visits and companionship. The detailed unit cost 
evidences in Table 3 provides good evidence for budget planning and cost efficiency. 
Similarly, in this respect, also highlighted that cost-of-illness evidence significant 
role in resource allocation, priority setting (Rice, 2000) and budget management 
(Rice, 1994). For instance, Tarricone (2006) highlighted its relevance in terms of 
estimating  the amount of resource consumption, cost identification, cost 
containment, clinical illness management and cost variability. 
ŒCONOMICA 
 203 
Table 3. Summary cost estimate for direct medical and direct non-medical per patient 
per year 
Cost per patient per year 
Urban Rural 
Mean (SD) Mean (SD) 
Direct medical cost  746.00 (749.68) 368.4 (161.91) 
Direct non-medical costs   
Transport cost (paid by the patient) 1,276.07 (3,099.38) 636.67 (349.31) 
Transport cost (paid by friends/ 
relatives/guardians ) 1,783.73 (1,470.39) 2,066.44 (2,193.88) 
Food costs (paid by the patient)  4,700.5 (4,226.35) 1,510.83 (376.18) 
Food costs (paid by friends/relatives/guardians 
) 811.29 (403.72) 832.78 (783.64) 
Accommodation expense (paid by the patient)  458.54 (1,157.1) 6.9 (37.14) 
Accommodation expense  
(paid by friends/ relatives/ guardians ) 0.0 (0.0) 19.67 (44.5) 
Total cost per patient per year 
9,776.13 (US$ 
496.99) 
5,441.7 (US$ 
276.6) 
SD = standard deviation 
 
3.5 National Cost Estimate 
Nationally, in 2014, at the current coverage and program uptake level, the estimated 
patient level cost was US$ 7,756,763.7 in urban settings, while it was US$ 2,730,825 
in rural areas. As shown in Figure 2, the estimated national patient cost increased 
with an increase in service coverage. In other words, when more HIV-positive 
pregnant women access the service, the estimated national patient-level cost for 
direct medical and non-medical costs increased. However, during the period 2011 to 
2016, there was an estimated decline in the number of HIV-positive pregnant women 
due to a lower HIV incidence (EPHI, 2014). As a result of the estimated decline in 
HIV prevalence, the national patient spending (for direct medical costs and direct 
non-medical costs) declined over time. Understanding the national perspective 
patient-level costs (in Figure 2) is important to highlight the overall economic burden 
on the society. There is already some evidence in Ethiopia that this information is 
needed as a number of studies (by Biadgilign et al., 2009; Pearson et al., 2011;  
Tekola et al., 2008; Ghailan et al., 2010)) have alluded to the consequences of the 
high costs of using HIV/AIDS services in the country. 
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Figure 2. National patient perspective cost in urban and rural settings, 2011- 2016 
 
4. Conclusion and Recommendation 
Although the HIV/AIDS care services are provided free of charge in Ethiopia, 
patients incurred substantial direct medical and direct non-medical costs, which 
probably affects the intended public health outcome for the HIV-positive pregnant 
women and pediatrics attending antiretroviral lifelong treatment. According to our 
analysis, an average pregnant woman (per year) attending the surveyed health 
facilities estimated to incur ETB 9,776.13 (US$ 496.99) and 5,441.7 (US$ 276.6) 
cost due to direct medical costs and direct non-medical costs, in urban and rural 
settings, respectively. Of these costs, transportation and food expenses were the main 
cost drivers, in both the urban and rural settings. In addition, the significance patient-
level cost differences across urban and rural settings also provide policy makers with 
important information on costs planning, priority-setting, budgeting, resource 
allocation and distribution.  The evidences in this study is crucial for Ethiopian health 
sector policy makers and program implementers seeking to improve access to 
PMTCT services, as well as on the current effort towards universal health coverage 
(UHC).  
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The study reports also a significant extra cost to friends/guardians/relatives while 
visiting the admitted patients or accompanying them to outpatient PMTCT treatment 
follow-up services. The estimated transportation costs paid by 
friends/guardians/relatives was ranged from ETB 1,783.73 (US $90.68) and 
2,066.44 (US$ 105.05) in urban and rural settings, respectively. In addition, the mean 
costs for food was ETB 811.29 (US$ 41.24) and ETB 832.78 (US$ 42.34) in urban 
and rural settings, respectively. Adding to the non-medical costs the direct costs per 
patient per year of ETB 746 (US$ 37.92) in the urban settings, and ETB 368.4 (US$ 
18.72) in the rural settings, increases even further the burden of HIV suffered by 
pregnant women and the household. Projecting its impact at the current national 
PMTCT coverage level, the patient level costs ranged from US$ 2,730,825 to US$ 
7,756,763.7 in rural and rural settings, respectively. 
It is finally worthwhile to acknowledge the limitation of this study. Due to the low 
PMTCT service uptake at the surveyed health facilities, this analysis depended on a 
limited sample size (85 HIV-positive pregnant women, 17 MSGs and 12 health care 
professionals). The sample makes it difficult to generalize the findings to the general 
population. The unit cost per pregnant women-infant pairs was used to estimate the 
national-patient perspective cost associated with mother-to-child HIV infection. 
However, this projection may be improved applying adequate and nationally 
representative sample size. A related shortcoming is that the study targeted HIV-
positive pregnant women accessing PMTCT services and did not include those who 
had not started or had defaulted on using the treatment. These limitations should be 
well taken into consideration along the study findings and interpretation. 
Despite these shortcomings, we believe that the findings are instrumental in 
highlighting the patient perspective costs resulting from HIV/AIDS transmission 
from mother-to-child in urban and rural settings. The analysis reported the direct 
medical and direct non-medical costs across the different contexts (urban high-HIV 
prevalence versus rural low-HIV prevalence), which could potentially inform the 
current country strategy towards the elimination of new mother-to-child HIV 
infections and current universal health coverage agenda. Finally the finding from this 
study is also crucial to provide relevant economic input evidence for further cost 
effectiveness analysis studies, considering the societal perspective.  
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